What is Pharmalink?
Pharmalink AB operates as a specialized entity within the pharmaceutical industry, headquartered in Stockholm, Sweden. With a lean, agile workforce of 20 to 49 employees, the company has demonstrated consistent revenue generation, currently reporting between 5M and 10M in annual turnover. The firm focuses on high-impact pharmaceutical development, positioning itself as a critical player in the Nordic biotech ecosystem. By maintaining a focused operational strategy, Pharmalink has successfully attracted institutional backing from prominent venture capital firms that prioritize scalable, science-driven innovations. Its market position is defined by a blend of technical expertise and a clear focus on addressing unmet medical needs through rigorous research and development protocols.
How much funding has Pharmalink raised?
Pharmalink has raised a total of $32.1M across 3 funding rounds:
Unspecified
$5.1M
Series C
$15M
Debt
$12M
Unspecified (2012): $5.1M with participation from Industrifonden
Series C (2013): $15M led by Investinor and Industrifonden
Debt (2015): $12M supported by Investinor and Industrifonden
Key Investors in Pharmalink
Investinor
Investinor AS is an investment company that collaborates with entrepreneurs, startups, and other investors to develop selected promising businesses into world leaders.
Industrifonden
Industrifonden is a Swedish venture capital fund that invests in unique, scalable innovations aimed at improving society through breakthrough technologies and science.
What's next for Pharmalink?
With the recent infusion of capital, Pharmalink is expected to prioritize the advancement of its core pharmaceutical assets and the expansion of its clinical development programs. The strategic focus will likely shift toward optimizing operational efficiencies and exploring new market opportunities that align with its long-term growth objectives. As the company transitions into this next phase of maturity, the emphasis will remain on maintaining its competitive edge through innovation and strategic partnerships. Investors will be closely monitoring the firm's ability to translate this recent financing into tangible clinical milestones and sustained revenue growth, ensuring that Pharmalink remains a formidable entity in the evolving pharmaceutical landscape.
See full Pharmalink company page
